Leal Therapeutics
Develops neuro-metabolic therapeutics for schizophrenia and ALS
$30MSeries A
Role not disclosedO
OrbiMed
Activity from announced rounds
Activity in this selectionUnited States
OrbiMed invests globally across healthcare, from early private companies to large public businesses, covering biopharmaceuticals, medical devices, diagnostics, digital health and healthcare services.
The team combines scientific, medical and investment expertise. Its capital and resources are tailored to the company, allowing the platform to support different development needs across a drug programme, a medical device or a care-delivery business.
Its private and public investment activity spans the healthcare company lifecycle. Founders can engage with a specialist healthcare investor while their technology is still developing, with expertise that also reaches clinical and commercial-scale businesses.
Sources
- Rounds participated in
- 8
- Confirmed lead rounds
- — 8 roles undisclosed
- New companies
- 8 First participation on record · 0 follow-on
- Funding in participating rounds
- $857M 7 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
8 in this selectionTytoCare
AI-first clinical enablement company and developer of remote physical examination technology featuring FDA-cleared medical devices
>$25MGrowth
Role not disclosedAccro Bioscience
Clinical-stage medicines targeting inflammation and regulated cell-death pathways in immune-mediated disease.
$50MSeries C
Role not disclosedTerremoto Biosciences
Develops highly targeted, small molecule medicines for cancer and rare diseases
$108MSeries C
Role not disclosedSidewinder Therapeutics
Develops next-generation bispecific ADCs for cancer treatment
$137MSeries B
Role not disclosedMendra
Develops and commercializes rare disease therapies using AI
$82MSeries A
Role not disclosedMirador Therapeutics
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
$250MSeries B
Role not disclosedAirNexis Therapeutics
AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01.
$200MSeries A
Role not disclosed